PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Interventions: Drug: Olaparib; Drug: Tremelimumab
Sponsors: New Mexico Cancer Care Alliance
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 12, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments